WEE1 Inhibitor: Clinical Development

被引：0
|
作者：
Anthony Kong
Hisham Mehanna
机构：
[1] University of Birmingham,Institute of Head and Neck Studies (InHANSE)
[2] King’s College London,Comprehensive Cancer Centre
来源：
Current Oncology Reports | 2021年 / 23卷
关键词：
WEE1 inhibitor; Adavosertib; AZD1775; TP53 mutation; Biomarker; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
    Roering, Pia
    Siddiqui, Arafat
    Heuser, Vanina D.
    Potdar, Swapnil
    Mikkonen, Piia
    Oikkonen, Jaana
    Li, Yilin
    Pikkusaari, Sanna
    Wennerberg, Krister
    Hynninen, Johanna
    Grenman, Seija
    Huhtinen, Kaisa
    Auranen, Annika
    Carpen, Olli
    Kaipio, Katja
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [22] Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor
    Mizuarai, Shinji
    Yamanaka, Kazunori
    Itadani, Hiraku
    Arai, Tsuyoshi
    Nishibata, Toshihide
    Hirai, Hiroshi
    Kotani, Hidehito
    MOLECULAR CANCER, 2009, 8
  • [23] Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study
    Mueller, Sabine
    Cooney, Tabitha
    Yang, Xiaodong
    Pal, Sharmistha
    Ermoian, Ralph
    Gajjar, Amar
    Liu, Xiaowei
    Prem, Komal
    Minard, Charles G.
    Reid, Joel M.
    Nelson, Marvin
    Haas-Kogan, Daphne
    Fox, Elizabeth
    Weigel, Brenda J.
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [24] WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer through Activation of Innate Immune Responses
    Li, Yinuo
    Wang, Xiangyu
    Hou, Xin
    Wu, Mingfu
    Wang, Shixuan
    Ma, Xiangyi
    JOURNAL OF CANCER, 2024, 15 (02): : 545 - 559
  • [25] CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1
    Pfeiffer, Christina
    Grandits, Alexander M.
    Asnagli, Helene
    Schneller, Anja
    Huber, Julia
    Zojer, Niklas
    Schreder, Martin
    Parker, Andrew E.
    Bolomsky, Arnold
    Beer, Philip A.
    Ludwig, Heinz
    LEUKEMIA, 2024, 38 (01) : 181 - 192
  • [26] Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells
    Ziener, Judy
    Henao-Restrepo, Julian Andres
    Leonhardi, Johanna
    Sturm, Max-Johann
    Becker, Sabine
    Morales-Prieto, Diana M.
    Milde, Till
    Beck, James F.
    Sonnemann, Juergen
    BMC CANCER, 2025, 25 (01)
  • [27] PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1
    Zhang, Qingyi
    Lin, Xu
    Jiang, Kan
    Deng, Jun
    Ke, Lei
    Wu, Ziheng
    Xia, Pinghui
    Li, Qi
    Yu, Li
    Ni, Pengzhi
    Lv, Wang
    Hu, Jian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells
    Meryem H. Cetin
    Thorsten Rieckmann
    Konstantin Hoffer
    Britta Riepen
    Sabrina Christiansen
    Fruzsina Gatzemeier
    Simon Feyerabend
    Melanie Schoof
    Ulrich Schüller
    Cordula Petersen
    Martin Mynarek
    Kai Rothkamm
    Malte Kriegs
    Nina Struve
    Radiation Oncology, 18
  • [29] G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells
    Cetin, Meryem H. H.
    Rieckmann, Thorsten
    Hoffer, Konstantin
    Riepen, Britta
    Christiansen, Sabrina
    Gatzemeier, Fruzsina
    Feyerabend, Simon
    Schoof, Melanie
    Schueller, Ulrich
    Petersen, Cordula
    Mynarek, Martin
    Rothkamm, Kai
    Kriegs, Malte
    Struve, Nina
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [30] ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
    Li, Jie
    Lu, Jingyi
    Xu, Manman
    Yang, Shiyu
    Yu, Tiantian
    Zheng, Cuimiao
    Huang, Xi
    Pan, Yuwen
    Chen, Yangyang
    Long, Junming
    Zhang, Chunyu
    Huang, Hua
    Dai, Qingyuan
    Li, Bo
    Wang, Wei
    Yao, Shuzhong
    Pan, Chaoyun
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (02)
12345